%0 Journal Article
%A Basset, Marco
%A Kimmich, Christoph R
%A Schreck, Nicholas
%A Krzykalla, Julia
%A Dittrich, Tobias
%A Veelken, Kaya
%A Goldschmidt, Hartmut
%A Seckinger, Anja
%A Hose, Dirk
%A Jauch, Anna
%A Müller-Tidow, Carsten
%A Benner, Axel
%A Hegenbart, Ute
%A Schönland, Stefan O
%T Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
%J British journal of haematology
%V 195
%N 2
%@ 1365-2141
%C Oxford [u.a.]
%I Wiley-Blackwell
%M DKFZ-2021-01748
%P 230-243
%D 2021
%Z 2021 Oct;195(2):230-243
%X Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68
%K AL amyloidosis (Other)
%K biomarkers (Other)
%K gain 1q21 (Other)
%K lenalidomide (Other)
%K prognosis (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34341985
%R 10.1111/bjh.17685
%U https://inrepo02.dkfz.de/record/170085